文献速递瓣膜外科

机械二尖瓣置换术后低剂量与标准剂量华法林比较:一项随机试验

Low-Dose vs Standard Warfarin After Mechanical Mitral Valve Replacement: A Randomized Trial.
PubMed 文献 · Ann Thorac Surg · 2023-01-04

PROACT二尖瓣随机对照非劣效性试验在44个北美中心纳入401例On-X机械二尖瓣置换术后患者,随机接受低剂量华法林(目标INR 2.0-2.5)或标准剂量华法林(目标INR 2.5-3.5),所有患者服用阿司匹林81 mg/日。平均随访4.1年,主要终点事件率低剂量组11.9%/患者年 vs 标准剂量组12.0%/患者年(差值-0.07%,95%CI -3.40%至3.26%),CI上限超过1.5%非劣效界值,非劣效性未达成。

要点

  • 低剂量华法林组平均INR 2.47 vs 标准剂量组2.92(P<.001)。
  • 主要终点事件率低剂量组11.9%/患者年 vs 标准剂量组12.0%/患者年,差值-0.07%(95%CI -3.40%至3.26%)。
  • 因CI上限超过1.5%非劣效界值,低剂量华法林未达到非劣效性。

核心结论

  • 与标准剂量华法林相比,低剂量华法林在复合主要终点上未达到非劣效性。

研究设计与样本

  • PROACT二尖瓣随机对照非劣效性试验,在44个北美中心纳入401例On-X机械二尖瓣置换术后且已接受至少3个月标准抗凝的患者,随机分为低剂量华法林组(目标INR 2.0-2.5)或标准剂量华法林组(目标INR 2.5-3.5),所有患者服用阿司匹林81 mg/日并鼓励使用家用INR检测。
  • 主要终点为血栓栓塞、瓣膜血栓和出血事件的线性化率之和,设计基于预期7.3%事件率和1.5%非劣效界值。

主要发现

  • 平均随访4.1年,低剂量组平均INR 2.47 vs 标准剂量组2.92(P<.001)。
  • 主要终点事件率低剂量组11.9%/患者年 vs 标准剂量组12.0%/患者年,差值-0.07%(95%CI -3.40%至3.26%)。
  • 主要终点各组分的率(%/患者年):血栓栓塞低剂量组2.3% vs 标准剂量组2.5%,瓣膜血栓0.5% vs 0.5%,出血9.13% vs 9.04%。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Current guidelines recommend a target international normalized ratio (INR) range of 2.5 to 3.5 in patients with a mechanical mitral prosthesis. The Prospective Randomized On-X Anticoagulation Clinical Trial (PROACT) Mitral randomized controlled noninferiority trial assessed safety and efficacy of warfarin at doses lower than currently recommended in patients with an On-X (Artivion, Inc) mechanical mitral valve. METHODS: After On-X mechanical mitral valve replacement, followed by at least 3 months of standard anticoagulation, 401 patients at 44 North American centers were randomized to low-dose warfarin (target INR, 2.0-2.5) or standard-dose warfarin (target INR, 2.5-3.5). All patients were prescribed aspirin, 81 mg daily, and encouraged to use home INR testing. The primary end point was the sum of the linearized rates of thromboembolism, valve thrombosis, and bleeding events. The design was based on an expected 7.3% event rate and 1.5% noninferiority margin. RESULTS: Mean patient follow-up was 4.1 years. Mean INR was 2.47 and 2.92 (P <.001) in the low-dose and standard-dose warfarin groups, respectively. Primary end point rates were 11.9% per patient-year in the low-dose group and 12.0% per patient-year in the standard-dose group (difference, -0.07%; 95% CI, -3.40% to 3.26%). The CI >1.5%, thus noninferiority was not achieved. Rates (percentage per patient-year) of the individual components of the primary end point were 2.3% vs 2.5% for thromboembolism, 0.5% vs 0.5% for valve thrombosis, and 9.13% vs 9.04% for bleeding. CONCLUSIONS: Compared with standard-dose warfarin, low-dose warfarin did not achieve noninferiority for the composite primary end point. (PROACT Clinicaltrials.gov number, NCT00291525).

来源:Ann Thorac Surg,查看原文。版权归原作者所有。

引用

  1. Chu MWA, Ruel M, Graeve A, et al. Low-Dose vs Standard Warfarin After Mechanical Mitral Valve Replacement: A Randomized Trial. Ann Thorac Surg. 2023. PMID: 36610532. doi:10.1016/j.athoracsur.2022.12.031

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。